A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors

NCT05716295 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped Corporate decision

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG: MDK-703
DRUG: Checkpoint Inhibitor, Immune

Sponsor

Medikine, Inc.